Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by topic

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Citation Tools

Research Article

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Kaufman HL, Andtbacka RHI, Collichio FA, et al

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Journal for ImmunoTherapy of Cancer 2017;5:72. doi: 10.1186/s40425-017-0276-8